US FDA permits small Phase II study for Repros' troubled Proellex
This article was originally published in Scrip
Executive Summary
The US FDA has lifted its full clinical hold on the development of Repros Therapeutics’ lead product Proellex (telapristone acetate, CDB-4124) to allow the company to run a small Phase II study of lower doses of the drug under a partial hold status.